We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

TIPPS: Thrombophilia in Pregnancy Prophylaxis Study (TIPPS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00967382
First Posted: August 27, 2009
Last Update Posted: May 19, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Ottawa Hospital Research Institute
May 29, 2009
August 27, 2009
May 19, 2014
July 2000
March 2014   (Final data collection date for primary outcome measure)
The primary objective of the study is to identify if LMWH prophylaxis in thrombophilic pregnant women results in a greater than 33% relative risk reduction in the composite outcome measure (VTE, pre-eclampsia, IUGR and fetal loss) [ Time Frame: 6 weeks post-partum ]
Same as current
Complete list of historical versions of study NCT00967382 on ClinicalTrials.gov Archive Site
  • Identify if prophylactic LMWH will reduce rates of pregnancy induced hypertension (PIH), preterm labor and abruptio placenta in pregnant thrombophilic women compared to control [ Time Frame: 6 weeks post-partum ]
  • Determine the safety of LMWH use in pregnancy (Specifically rates of bleeding, thrombocytopenia and fractures) [ Time Frame: 6 weeks post-partum ]
  • Identify whether prolonged use of LMWH in pregnancy results in decreased bone mineral density (BMD) compared to control [ Time Frame: 6 weeks post-partum ]
  • Identify if prophylactic LMWH will reduce rates of PIH, preterm labor and abruptio placenta in pregnant thrombophilic women compared to control [ Time Frame: 6 weeks post-partum ]
  • Determine the safety of LWH use in pregnancy (Specifically rates of bleeding, thrombocytopenia and fractures) [ Time Frame: 6 weeks post-partum ]
  • Identify whether prolonged use of LMWH in pregnancy results in decreased BMD compared to control [ Time Frame: 6 weeks post-partum ]
Not Provided
Not Provided
 
TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.
The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent thrombosis in the leg veins, pulmonary arteries and placental vessels, thereby reducing the risk of deep vein thrombosis, pulmonary embolism (PE), intrauterine growth restriction (IUGR), preeclampsia, miscarriage and stillbirth?

TIPPS is a multicentre, multi-national open-label randomized controlled clinical trial. Two hundred and eighty-four thrombophilic women at risk for VTE or placenta mediated pregnancy complications will be recruited. Patients who require anticoagulant prophylaxis during this pregnancy (as judged by the local investigator) or have participated in TIPPS before will not be eligible for the trial.

The study consists of five periods: screening, randomization, antenatal follow-up, labour and delivery, and the post-partum follow-up.

Eligible and consenting patients will be assigned to one of two groups (treatment or control), stratified by gestational age at randomization: less than 8 weeks, 8 weeks +1 day to 12 weeks , 12 weeks +1 day to 19 weeks + 6 days.

Treatment Group - Subjects randomized to the treatment group will receive daily injections of dalteparin during the ante-natal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 International units (IU) once daily (o.d.) until gestational week 20, then twice daily (bid) until 37 weeks gestation or onset of labour.

Control Group- Subjects randomized to control will receive identical obstetrical care and follow-up, but no ante-natal dalteparin.

Visit Schedule Subject will be evaluated for study eligibility and once the consent has been signed a baseline assessment will be completed. Randomization is done within 7 days of the baseline visit.

All patients will be seen in person for the first follow-up visit 7-9 days after randomization. Subsequent visits are based on the gestational age of the fetus and will be as follows:

  • Monthly (+/- 1 week) from gestational week 8 to 28 -
  • Every 2 weeks (+/- 1 week) from gestational week 28 to 34
  • Every week from gestational week 35 until delivery.

The following visits are required in-person at day 7-9 and at gestational weeks 12, 20, 28, 32 and/or 36 and at 6 weeks post-partum to coincide with safety blood draws for hematology and biochemistry regardless of treatment allocation.

The remaining visits can be done in person or by phone calls: at gestational weeks 8, 16, 24, 30, 34, 35, 37, 38, 39 and 40. If available, results for hematology and biochemistry done at gestational age 8, 16, 24 and 40 will be recorded.

At each visit, weight and blood pressure measurements will be recorded and all subjects will be monitored for study progress, study outcomes, adverse events (AEs), and concomitant medications. Subjects randomized to receive dalteparin will have their compliance assessed through the monthly visits. Subjects will be required to complete the patient injection diary and will be asked to bring it with them at all in-person-visits. The diary will be collected at the completion of study participation.

Labour and delivery: outcomes and AEs will be assessed through a review of subjects' medical records. If available, results from blood drawn for hematology and biochemistry will be recorded. Data pertaining to the labour and delivery, as well as foetal weight and health at birth, will be documented. For those subjects randomized to receive dalteparin, the date and time of the last injection will be noted.

During the six-week postpartum period, all subjects will receive dalteparin 5,000 IU o.d. for VTE prophylaxis. Subjects randomized to control will be taught to self-administer the subcutaneous injections prior to starting their postpartum injections. Subjects will be asked to complete the patient injection diary and to return it at the final visit. The final study visit occurs at 6 weeks post-partum (+/- 1week) or at early termination; at this visit study progress, study outcomes, adverse events, results from blood drawn for hematology and biochemistry and compliance with study drug will be documented.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Pregnancy
  • Thrombophilia
  • Pregnancy Complications
Drug: dalteparin sodium

Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;

dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)

Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum

Other Name: Fragmin
  • No Intervention: Control

    Subjects randomized to control will receive identical obstetrical care and follow-up, but not antenatal dalteparin.

    Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum

  • Active Comparator: dalteparin sodium

    Subjects randomized to the treatment group will receive daily injections of dalteparin during the antenatal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 IU once daily (o.d.) until gestational age 20, then twice daily (bid) until 37 weeks gestation or onset of labour.

    Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum

    Intervention: Drug: dalteparin sodium

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
292
March 2014
March 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

One or more of the following:

  • Previous preeclampsia
  • Previous unexplained intra-uterine growth restriction
  • Previous recurrent miscarriage:

    • three(3) or more unexplained miscarriage at less than 10 weeks gestation;
    • two (2) or more unexplained fetal loss between 10 and 16 weeks gestation;
    • one (1) or more unexplained fetal loss at or greater than 16 weeks gestation
  • Previous abruptio placenta
  • Previous personal history of VTE:

    • Previous documented secondary proximal VTE,
    • Previous documented calf-vein thrombosis (idiopathic or secondary),
    • Previous superficial phlebitis
  • First degree relative with symptomatic thrombophilia
  • Pregnancy - > 4weeks gestation and < 20 weeks gestation
  • Thrombophilia:
  • Two abnormal tests, and no normal tests

    • 3.1 Protein S
    • 3.2 Protein C
    • 3.3 Antithrombin
  • Two positive tests

    • 3.4 Anticardiolipin immunoglobulin M (IgM) (>30 U/ml)
    • 3.5 Anticardiolipin immunoglobulin G (IgG) (>30 U/ml)
    • 3.6 Anti-b2 glycoprotein IgG (>20 U/ml)
    • 3.7 Anti-b2 glycoprotein IgM (>20 U/ml)
    • 3.8 Lupus anticoagulant
  • One positive test

    • 3.9 Factor V Leiden (heterozygous or homozygous)
    • 3.10Prothrombin gene defect (heterozygous or homozygous)

Exclusion Criteria:

  • Less than 4 weeks gestation or greater than 20 weeks gestation
  • No confirmed thrombophilia
  • Contraindication to heparin therapy

    • History of heparin induced thrombocytopenia
    • Platelet count less than 100,000 109/L
    • History of osteoporosis or steroid use
    • Actively bleeding
    • Documented peptic ulcer within 6 weeks
    • Heparin, bisulfite or fish allergy
    • Severe hypertension (Systolic Blood Pressure >200mmhg and/or Diastolic Blood Pressure >120mmHg)
    • Serum creatinine greater than 80 umol/L (1.3mg/dl) and an abnormal 24 hour urine creatine clearance (<30ml/min)
    • Severe hepatic failure (INR >1.8)
  • Geographic inaccessibility
  • Need for anticoagulants, discretion of the investigator such as but not limited to:

    • Recurrent fetal loss and phospholipid antibody syndrome
    • Prior idiopathic proximal VTE:
    • History of idiopathic deep venous thrombosis (DVT) or pulmonary embolism (PE) treated with anticoagulants (> 1 month of heparin or warfarin) or inferior vena cava (IVC) interruption;
    • Idiopathic is a VTE occurring outside all of the following periods: antepartum, postpartum, oral contraceptive use, surgery, immobilization, cast, and malignancy
    • Mechanical heart valve
  • Legal lower age limitations (country specific)
  • Prior participation in TIPPS
  • Unable/unwilling to provide informed consent
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT00967382
1999210-01H
IND 72,350 ( Other Identifier: Department of Health & Human Services, FDA )
ISRCTN 87441504 ( Registry Identifier: ISRCTN )
CIHR 200602MCT-157533-RFA ( Other Grant/Funding Number: Canadian Institutes of Health Research )
Trial number 2004/244 ( Other Identifier: Australian Government,Therapeutic Goods Administration )
2007-000284-21 ( EudraCT Number )
Yes
Not Provided
Not Provided
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR)
Principal Investigator: Marc A Rodger, MD Ottawa Hospital Research Institute, Ottawa, Canada
Principal Investigator: William Hague, MD Women's and Children's Hospital, Adelaide, Australia
Ottawa Hospital Research Institute
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP